ArticleHepatology international2021
Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
Yuan-Hung Kuo et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papercites it